白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2015年
5期
290-294
,共5页
周继豪%孙璇%林海清%孙雄飞%姜容%张新友
週繼豪%孫璇%林海清%孫雄飛%薑容%張新友
주계호%손선%림해청%손웅비%강용%장신우
树突状细胞肿瘤%母细胞%浆细胞样树突状细胞
樹突狀細胞腫瘤%母細胞%漿細胞樣樹突狀細胞
수돌상세포종류%모세포%장세포양수돌상세포
Dendritic cell neoplasm%Blastic%Plasmacytoid dendritic cells
目的 提高对母细胞性浆细胞样树突状细胞肿瘤(BPDCN)的认识.方法 通过1例病例报告和文献复习,分析BPDCN患者的临床特点、治疗选择及预后.结果 BPDCN患者以中老年男性居多,绝大多数发病时表现为皮疹和骨髓浸润,特征性免疫表型为CD4+、CD56+、CD123+.在诱导治疗方面,淋系方案比髓系方案治疗的总反应率高,复发率较低,总生存较长.异基因造血干细胞移植可能带来长期生存.患者发病时白细胞和血小板总数可能是影响BPDCN预后的危险因素.结论 BPDCN在临床表现和免疫表型上都具有显著特点,治疗方案建议以淋系方案为主,在首次完全缓解期行异基因造血干细胞移植是改善预后、获得远期生存的重要手段.
目的 提高對母細胞性漿細胞樣樹突狀細胞腫瘤(BPDCN)的認識.方法 通過1例病例報告和文獻複習,分析BPDCN患者的臨床特點、治療選擇及預後.結果 BPDCN患者以中老年男性居多,絕大多數髮病時錶現為皮疹和骨髓浸潤,特徵性免疫錶型為CD4+、CD56+、CD123+.在誘導治療方麵,淋繫方案比髓繫方案治療的總反應率高,複髮率較低,總生存較長.異基因造血榦細胞移植可能帶來長期生存.患者髮病時白細胞和血小闆總數可能是影響BPDCN預後的危險因素.結論 BPDCN在臨床錶現和免疫錶型上都具有顯著特點,治療方案建議以淋繫方案為主,在首次完全緩解期行異基因造血榦細胞移植是改善預後、穫得遠期生存的重要手段.
목적 제고대모세포성장세포양수돌상세포종류(BPDCN)적인식.방법 통과1례병례보고화문헌복습,분석BPDCN환자적림상특점、치료선택급예후.결과 BPDCN환자이중노년남성거다,절대다수발병시표현위피진화골수침윤,특정성면역표형위CD4+、CD56+、CD123+.재유도치료방면,림계방안비수계방안치료적총반응솔고,복발솔교저,총생존교장.이기인조혈간세포이식가능대래장기생존.환자발병시백세포화혈소판총수가능시영향BPDCN예후적위험인소.결론 BPDCN재림상표현화면역표형상도구유현저특점,치료방안건의이림계방안위주,재수차완전완해기행이기인조혈간세포이식시개선예후、획득원기생존적중요수단.
Objective To provide new information for treatment and prognosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN).Methods Through one case report and literature review of 48 BPDCN cases were reviewed retrospectively.The clinical characteristics,treatment choices and prognosis were analyzed.Results BPDCN patients were mainly elderly males,mostly presented as skin rash and bone marrow infiltration.Immunophenotype was characteristically expressed as CD4,CD56 and CD123.Lymphoid-like regimens could induce higher response rate,lower relapse rate and longer overall survival compared with myeloid-like regimens.Allogeneic hematopoietic stem cell transplantation may provide long-term survival.At the onset of the disease,The counts of white blood cells (WBC) and blood platelet (Plt) may be correlated with inferior overall survival.Conclusions BPDCN is a disease with distinct clinical characteristics and immunophenotype.Lymphoid-like regimen may be the better treatment of choice,while allogeneic hematopoietic stem cell transplantation should be taken into account in the first complete remission for longterm survival.